Core Viewpoint - The article discusses the implications of Canada's submission to U.S. trade pressures, highlighting the broader risks for other nations and the potential for a fragmented global economy due to U.S. trade policies [1][22]. Group 1: U.S. Trade Strategy - The U.S. employs a "poison pill" strategy, using tariffs as a tool to create pressure on countries, while the real danger lies in the hidden clauses related to "national security" and "reliable supply chains" [3][5]. - The U.S. has set a deadline for countries to comply with its trade demands, creating a sense of urgency and fear among nations to avoid economic repercussions [5][17]. Group 2: Canada's Economic Vulnerability - Canada is heavily reliant on the U.S. for trade, with 75% of its exports going to the U.S., making it particularly susceptible to U.S. tariffs [8][10]. - The economic strain from U.S. pressures has led to a shrinking GDP and rising unemployment in Canada, further weakening its ability to resist U.S. demands [8][10]. Group 3: China's Response - China has shifted its strategy from reactive measures to proactive warnings, clearly stating that any country compromising Chinese interests for U.S. tariff exemptions will face consequences [12][13]. - China is working on building a new economic system that reduces reliance on the U.S. and strengthens ties with other economies, such as ASEAN and BRICS [15][20]. Group 4: Global Implications - Canada's capitulation serves as a warning to other nations, with countries like Japan, South Korea, and India showing signs of following suit in negotiations with the U.S. [17][18]. - The potential normalization of "poison pill" clauses in global trade agreements could lead to a fragmented world economy, characterized by geopolitical divisions and increased trade costs [20][22].

Group 1 - The core point of the news is that Kexing Bio has announced a special cash dividend of $55 per share, which is 8.5 times its stock price of $6.47 before suspension, and plans additional dividends of $19 and a potential third dividend ranging from $20 to $50 per share [1] - Kexing Bio's financial performance has shown significant cyclicality, with total profits of $240 million from 2015 to 2020, a peak net profit of $14.5 billion in 2021 due to the COVID-19 pandemic, and losses in 2023 and the first half of 2024, yet the board decided to implement a large-scale cash dividend plan reflecting substantial cash reserves accumulated during the pandemic [2] - The control dispute over Kexing Bio dates back to 2016, involving a legal battle between the actual controller Yin Weidong and former chairman Pan Aihua, leading to aggressive tactics such as power cuts and asset seizures, with a recent lawsuit from Weiw Capital claiming the board's actions are irresponsible and favoring certain shareholders [3]